INTRODUCTION
============

Glioblastoma multiforme (GBM), a grade IV glioma, is the most common and most aggressive primary brain tumor \[[@B1]\]. Additionally, GBM is highly malignant having poor prognosis, with a median survival of 12 to 15 months \[[@B2]\]. The standard therapy for GBM is surgery followed by radiation and chemotherapy. The effect of currently used chemotherapeutic drug Temozolomide is not satisfactory since there is no significant improvement in patient survival. Furthermore, a number of genetic alterations including several cell signaling pathway genes are involved in GBM pathogenesis. One such alteration that occurs frequently in GBM is aberrant expression of Notch signaling pathway genes. The Notch signaling pathway plays a critical role in maintenance and self-renewal of neural stem cells \[[@B3]\]. Since Notch pathway is involved in maintaining cells in an undifferentiated state, dysregulated Notch genes have been associated with a growing list of cancers including T-cell acute lymphoblastic leukemia, Hodgkin lymphoma, multiple myeloma, glioma, cervical, pancreatic, lung, breast cancer, hepatocellular carcinoma, etc. \[[@B4][@B5]\]. In an attempt to better understand GBM, several studies have examined genetic alterations in Notch signaling pathway \[[@B6][@B7][@B8]\]. Also, Notch inhibition has been shown to result in decreased proliferation and self-renewal of GBM cells in several instances \[[@B9][@B10][@B11]\]. Notch signaling pathway has thus proved to be a novel therapeutic target in the treatment of GBM.

Numerous studies have documented various herbal products as novel anticancer drugs for efficient cancer treatment. Currently used chemotherapeutic agents are systemic and cause harmful side effects. Compared to highly toxic and expensive chemotherapeutic agents, herbal products have enabled the development of safer, nontoxic and affordable treatment for cancer. Bacoside A is the most studied constituent of *Bacopa monnieri*, locally known as Brahmi. Brahmi has been used for centuries in Ayurveda as a rejuvenating herb for nerve and brain cells development because of its neuroprotective properties. *Bacopa monnieri* has been found to have antioxidant properties which is used to treat oxidative stress caused due to aging and cigarette smoke \[[@B12][@B13]\]. It is observed to inhibit intraneuronal lipofuscin accumulation and necrotic alteration caused due to neurotoxicity in the hippocampus \[[@B14]\]. Its ability to cross the blood brain barrier has been exploited in the treatment of Alzheimer\'s and Parkinson\'s disease, attention deficit disorder, etc. Additionally, *Bacopa monnieri* as a crude plant extract or as individual constituents have been used in the treatment of cancer. However, the antitumor property of Brahmi has not been studied extensively in recent times. Various *in vitro* and *in vivo* studies have shown cytotoxic and antiproliferative properties of *Bacopa monnieri* whole plant extract \[[@B15][@B16]\]. Furthermore, research have suggested that the anticancer effect of *Bacopa monnieri* extracts is possibly due to inhibition of DNA replication, DNA fragmentation and activation of apoptotic pathway \[[@B17][@B18]\]. Collectively, these data suggest that Brahmi emerges as a promising therapy and further research needs to be done to check the antitumor property of the herb in treating GBM.

In the present study, we explored the antitumor properties of a bioactive phytochemical Bacoside A in human GBM cell line U-87 MG and its effects on the expression of Notch signaling pathway genes. This could enhance our understanding of the role of Notch genes in GBM and present a specific molecular target for developing a much needed herbal therapy to treat GBM.

MATERIALS AND METHODS
=====================

Cell culture
------------

Human Glioblastoma cell line U-87 MG (ATCC, Manassas, VA, USA) was cultured in DMEM (Sigma Aldrich, St. Louis, MO, USA) supplemented with 10% FBS (Invitrogen, Camarillo, CA, USA). The cells were cultured in T25 flasks and grown in a humidified 5% CO~2~ incubator at 37℃. The cells were trypsinized and sub cultured on reaching 70--80% confluence. Bacoside A (Natural Remedies, Bangalore, India) was dissolved in HPLC grade methanol (Fisher Scientific, Waltham, MA, USA) to obtain a stock solution of 3.2 mg/mL concentration by making up the volume with DMEM. After preliminary dose response studies (data not shown), working solutions were prepared from the stock at concentrations of 320, 160, 80, 40, 20, 10, and 5 µg/mL with DMEM.

MTT assay
---------

The cells were seeded in a 96-well plate with 50,000 cells per well in medium and incubated for 24 h at 37℃, 5% CO~2~ and 95% air atmosphere. After 24 h incubation, cells were treated with different concentrations of Bacoside A (320, 160, 80, 40, 20, 10 and 5 µg/mL), each in triplicate for another 24 h. The cells were then harvested and washed with 1× PBS (HiMedia, Mumbai, India). 100 µL of MTT (0.5 mg/mL) (Sigma Aldrich) was added to each well and incubated for 3.5 h at 37℃ before 100 µL of 100% DMSO (HiMedia) was added. The absorbance was measured on a microplate reader (Tecan, Männedorf, Switzerland) at a wavelength of 490 nm. The solvent methanol treated cells served as control. The final concentration of methanol in culture medium did not exceed 1% and was proved not to affect the experiment. Percentage inhibition was expressed using the following formula:

IC~50~ value was determined by plotting % inhibition on y-axis against concentration of Bacoside A on x-axis which gives the concentration of drug required for 50% inhibition. IC~50~ values were derived from a non-linear regression model (curvefit), computed using GraphPad Prism (La Jolla, CA, USA).

Cell cycle analysis
-------------------

Cell cycle analysis was performed by flow cytometry using propidium iodide (PI) based measurements of the DNA content in the cells. Briefly, U-87 MG cells were treated with 80 µg/mL and 100 µg/mL Bacoside A for 24 h. Treated and untreated cells were harvested and washed twice with 1× PBS (4,000 rpm, 10 min, 25℃). Thereafter, cells were fixed with 70% ice cold ethanol and stored at 4℃ overnight. The cells were then washed twice with 1× PBS (4,000 rpm, 10 min, 25℃). Later, cells were stained with 500 µL of PI (0.05 mg/mL in PBS containing 0.05 mg/mL RNase A) for 15 min at room temperature in dark. Cells were analyzed for DNA content on a FACSCalibur™ flow cytometer using Cell Quest acquisition and analysis software (Becton Dickinson, Heidelberg, Germany).

Apoptosis assay
---------------

U-87 MG cells were incubated with 80 µg/mL and 100 µg/ mL Bacoside A for 24 h before the cells were harvested. The treated and untreated cells were washed twice in 1× PBS (4,000 rpm, 10 min, 25℃), and the cell pellet obtained was resuspended in Annexin V binding buffer at room temperature to a concentration of 1×10^6^ cells/mL. To the resuspended solution, 5 µL of Annexin V-FITC and 5 µL of PI were added. The resulting mixtures were gently mixed and incubated for 15 min at room temperature in dark. An additional 400 µL of binding buffer was added to each tube and flow cytometric evaluation was conducted immediately on a FACSCalibur™ flow cytometer using Cell Quest acquisition and analysis software (Becton Dickinson).

Fluorescence microscopy
-----------------------

The Annexin V-FITC/PI staining procedure of the treated and untreated cells was performed as above. After staining, 20 µL of sample was mounted onto a glass slide with a cover slip and observed under 40× objective lens of fluorescence microscope (Lawrence & Mayo, Mumbai, India). Images of cells were obtained with a digital camera (DSC-W830, Sony, Tokyo, Japan) connected to the microscope.

DNA fragmentation analysis
--------------------------

U-87 MG cells were cultured for 24 h before treating with 80 µg/mL and 100 µg/mL of Bacoside A and grown at 37℃ in a humidified 5% CO~2~ incubator for 24 h. At the end of treatment, both floating cells and adherent cells were harvested. Genomic DNA was isolated from treated and untreated cells by TRIzol (Invitrogen) method as recommended by the manufacturer. DNA samples were mixed with loading dye (Bangalore GeNei, Bangalore, India) and resolved in 1% agarose gel (Lonza, Basel, Switzerland) containing 0.5 µg/mL ethidium bromide (Sigma Aldrich). Electrophoresis was carried out at 75 V for 60 min using 1× TAE buffer (0.04 M Tris acetate, 0.001 M EDTA, pH 8.2). After electrophoresis, DNA in the gel was visualized and photographed in a gel documentation system (UVItec, Cambridge, UK).

RNA isolation and reverse transcription
---------------------------------------

U-87 MG cells were treated with 80 µg/mL of Bacoside A corresponding to their IC~50~ value for 24 h. Treated and untreated cells were harvested and total RNA was extracted by TRIzol (Invitrogen) method as recommended by the manufacturer. RNA samples extracted were quantified using NanoDrop 1,000 spectrophotometer (Thermo Scientific, DE, USA). 1 µg of RNA was reverse transcribed to cDNA using high-capacity cDNA reverse transcription kit (Applied Biosystems, CA, USA) as per manufacturer\'s protocol.

Quantitative real-time PCR
--------------------------

The relative quantitation of expression levels of eight Notch pathway genes (*notch1*, *notch2*, *notch3*, *notch4*, *jagged1*, *jagged2*, *APH1A* and *HES1*) was carried out on Applied Biosystems StepOnePlus™ Instrument (CA, USA). Amplification was performed using SYBR Green master mix (Fermentas, MA, USA), 150 nM forward and reverse primer (Sigma Aldrich) and 20 ng of cDNA template. Amplification was carried out with an initial denaturation step at 95℃ for 10 min followed by 45 cycles at 95℃ for 15 s, 57℃ for 30 s and 72℃ for 30 s in a total of 12.5 µL reaction volume. All reactions were run in triplicates and the mean was used for further calculations. TATA binding protein (TBP), a housekeeping gene was chosen as an appropriate internal control after validating four conventionally used housekeeping genes (*GAPDH*, *TBP*, *B2M* and *RPL13A*) in gene expression studies (data not shown). Untreated cells were used as calibrator. Relative quantification was done by 2^−ΔΔCt^ method, the data are presented as fold change in gene expression normalized to an endogenous reference gene and relative to the calibrator, and is given by:

Statistical significance was assessed by calculating probability values through Student\'s t test using GraphPad. *p* values less than 0.05 were considered as significant.

RESULTS
=======

Cytotoxicity
------------

Cytotoxic effect of Bacoside A was evaluated on U-87 MG cells using the MTT colorimetric assay. Results indicated that Bacoside A possessed dose-dependent cytotoxic effects against human GBM cells ([Fig. 1](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}). It is evident from the results in the [Table 1](#T1){ref-type="table"} that the cell viability was not significantly affected at concentrations up to 20 µg/mL of Bacoside A, which retained 80.88% of viable cells. However, 74.21% inhibition was observed at concentration 320 µg/mL. Thus, to exclude the cytotoxicity of excess Bacoside A, IC~50~ value was determined and found to be 83.01 µg/mL against U-87 MG cell line.

Cell cycle arrest
-----------------

In order to evaluate the effects of Bacoside A on cell cycle, U-87 MG cells were treated with the drug at 80 µg/mL and 100 µg/mL concentration for 24 h. DNA content in sub-G0 phase, G0/G1 phase, S phase, and G2/M phase were determined at the end of the treatment by flow cytometry. [Fig. 2](#F2){ref-type="fig"} and 3 shows the effects of Bacoside A on sub-G0 phase, G0/G1 phase, S phase and G2/M phase in U-87 MG cells after 24 h treatment. Untreated cells showed a normal cell cycle with hardly any sub-G0 DNA ([Fig. 2A](#F2){ref-type="fig"}, [Fig. 3](#F3){ref-type="fig"}). Treatment with Bacoside A caused a significant increase in sub-G0 phase, indicative of apoptosis. This increase in sub-G0 cell population was accompanied with a decrease in the population of cells in G0/G1, S and G2/M phase. The treatment at 80 µg/mL concentration caused an arrest of 39.21% cells in sub-G0 phase, further increasing to 53.21% at the higher concentration of 100 µg/mL compared to untreated cells (0.37%) (*p*=0.022) ([Fig. 2B and C](#F2){ref-type="fig"}, [Fig. 3](#F3){ref-type="fig"}). Thus, these results revealed that an increase of Bacoside A concentration led to increased apoptosis in human GBM cell line.

Apoptosis
---------

By staining Bacoside A treated U-87 MG cells with Annexin V-FITC and PI, flow cytometry was carried out to determine the percentage of apoptotic and necrotic cells after 24 h treatment. The percentage of viable U-87 MG cells (AnV−/PI−) after 80 µg/mL and 100 µg/mL of Bacoside A treatment decreased to 67.77% and 58.56% respectively when compared with the untreated control (93.87%) (*p*=0.021). Furthermore, the percentage of early apoptotic cells (AnV+/PI−) increased from 3.48% in untreated control cells to 31.36% and 41.11% in 80 µg/mL and 100 µg/mL of Bacoside A treated cells respectively (*p*=0.021) ([Fig. 4](#F4){ref-type="fig"}). Thus, Bacoside A induces early apoptosis in human GBM cell line in a dose dependent manner.

Fluorescence microscopy
-----------------------

U-87 MG cells treated with Bacoside A were stained with Annexin V-FITC/PI and observed under a fluorescence microscope. Bacoside A treated cells when stained with PI displayed red fluorescence due to fragmented chromatin and green fluorescence on the cell membrane when stained with Annexin V-FITC. Different labelling patterns enabled identification of different cell populations. Early apoptotic cells showed affinity towards Annexin V-FITC alone and were devoid of PI ([Fig. 5A](#F5){ref-type="fig"}). Late apoptotic/necrotic cells showed affinity for both Annexin V-FITC and PI displaying red nucleus and a halo of green on the cell surface ([Fig. 5B](#F5){ref-type="fig"}). Dead cells showed affinity towards PI alone indicating completely degraded cell membrane ([Fig. 5C](#F5){ref-type="fig"}).

DNA fragmentation
-----------------

DNA from Bacoside A treated U-87 MG cells showed DNA ladder formation ([Fig. 6](#F6){ref-type="fig"}) which is a hallmark property of apoptosis further confirming the induction of cell death by the drug. However, DNA from the control cells was not degraded. Together, these results could indicate that Bacoside A induces apoptosis in human GBM cells *in vitro*.

Gene expression
---------------

To examine if Bacoside A induced cell death via Notch signaling pathway, we studied expression of eight Notch pathway genes by real-time PCR to determine whether Notch pathway genes were modulated by Bacoside A. Bacoside A did not affect the expression levels of *notch2*, *notch3*, *notch4*, *JAG1*, *JAG2* and *APH1A* genes as compared to the untreated control cells ([Fig. 7](#F7){ref-type="fig"}). However, the expression of Notch receptor *notch1* was decreased significantly with a fold change of 0.05 (*p*=0.005) and the expression of Notch downstream target *HES1* was increased by 25 fold after 80 µg/mL of Bacoside A treatment for 24 h (*p*=0.017) ([Table 2](#T2){ref-type="table"}, [Fig. 7](#F7){ref-type="fig"}). These results provide added data for Bacoside A induced apoptosis via the Notch signaling pathway in U-87 MG cells.

DISCUSSION
==========

GBM is a complex disease which is extremely refractory to therapy, in part because of poor understanding of several genetic alterations involved in its pathogenesis. Most of the patients who succumb to GBM within one year despite advance treatment highlight the need for better therapies acting at the genetic level. In recent years, herbal therapy has gradually emerged as a novel cancer treatment having a huge advantage over conventional chemotherapeutics. The common features of inducing cell cycle arrest and apoptosis by chemotherapic agents in cancer cells are the focus of this study. We investigated the anticancer property of Bacoside A which is the most studied component of *Bacopa monnieri*, against human GBM cell line U-87 MG. Untreated cells were used as experimental control in this study. Bacoside A has gained significant attention in recent years as a lead for the development of anticancer therapeutics \[[@B19][@B20][@B21]\]. It is a blend of bacoside A3, bacopacide II, bacopasaponin C, and a jujubogenin isomer of bacosaponin C \[[@B22]\]. It is however found to be safe and nontoxic on normal cells making it a suitable therapeutic lead \[[@B23][@B24][@B25]\]. The aim of this work was to determine the effects of Bacoside A on cell cycle arrest and apoptosis with associated impact on expression of Notch pathway genes in human GBM cell line U-87 MG.

Evaluation of cytotoxicity revealed that Bacoside A showed dose-dependent cytotoxicity against U-87 MG cells. The IC~50~ value was found to be less than 100 µg/mL signifying potent cytotoxic effects in GBM cells. We investigated the cell cycle specific effects of Bacoside A against human GBM cells by PI based cell cycle analysis using flow cytometry. Cancer cell cycle specific drugs cause cell death by blocking cell cycle at specific cell cycle checkpoints (sub-G0, G0/G1 phase, S phase and G2/M phase) \[[@B26]\]. These drugs could induce apoptosis (sub-G0 arrest) or inhibit cell proliferation (G0/G1 phase arrest), or DNA replication (S phase arrest) or mitosis (G2/M phase arrest) \[[@B27]\]. The flow cytometry result showed an arrest of 39.21% cells in sub-G0 phase at 80 µg/mL concentration, further increasing to 53.21% at the higher concentration of 100 µg/mL after 24 h. It is possible that the toxic effect of high doses of Bacoside A may inhibit the enzymes associated with cell cycle. The significant arrest of cells at sub-G0 phase is indicative of apoptosis thus suggesting that Bacoside A act by cell cycle-specific mechanism inducing apoptosis in GBM cells.

Most anti-cancer drugs eliminate rapidly proliferating cancerous cells, by inducing apoptosis \[[@B28]\]. Apoptosis is characterized by disintegration of plasma membrane, enzymatic cleavage of the DNA into fragments, and formation of apoptotic bodies \[[@B29]\]. We investigated the induction of apoptosis in GBM cells upon treatment with Bacoside A. Annexin V-FITC/PI assay by flow cytometry revealed that Bacoside A induced early apoptosis, but not necrosis, in GBM cells. Consistent with the MTT assay, the Annexin V-FITC/PI staining and DNA fragmentation studies demonstrated significant growth inhibitory effect of Bacoside A on GBM cells. DNA fragmentation which is a hallmark property of apoptosis further confirmed apoptosis in GBM cells. Furthermore, the morphology of the cells changed and the number of viable cells decreased under microscopic examinations.

Treatment of GBM cells with Bacoside A decreased *notch1* expression and increased the levels of *HES1* expression. Numerous studies have documented a direct correlation between high levels of *notch1* expression and GBM pathogenesis \[[@B8][@B30]\]. Induced overexpression of *HES1* *in vitro* and *in vivo* led to growth arrest and apoptosis in acute myeloid leukaemia and hepatocellular carcinoma supporting the tumour suppressor role of *HES1* in these cancers \[[@B31][@B32][@B33]\]. Furthermore, gastric and prostate cancer cells with lower levels of *notch1* were prone to apoptosis and decreased cell proliferation \[[@B34][@B35]\]. Pretreatment of glioma cells with Notch1 siRNA prolonged survival in a murine orthotopic brain tumor model \[[@B8]\]. Furthermore, inhibition of Notch signaling through knockdown of notch receptors in GBM resulted in significant reduction in cell growth *in vitro* and *in vivo* \[[@B9]\]. Notch blockade in GBM derived neurosphere cultures by gamma secretase inhibitors reduced neurosphere growth and stem cell markers \[[@B36]\]. Additionally, there are studies showing increased expression of *HES1* due to interference with *notch1* expression inhibiting glioma cancer cells growth by inducing cell autophagy \[[@B37]\] and overexpression of *HES1* inhibiting Notch1 signaling which in turn decreased tumor-initiating subpopulation in breast cancer \[[@B38]\]. Thus, these studies evidently display the oncogenic property of *notch1* gene and tumor suppressor role of *HES1* gene. Therefore, we report here that Bacoside A induced apoptosis in GBM cells *in vitro* may be dependent on Notch signaling pathway. The decreased levels of *notch1* and increased levels of *HES1* may, in part, account for the high susceptibility of GBM cells to cell cycle arrest and apoptosis in response to Bacoside A.

Taken together, alterations in the expression of few Notch genes, DNA fragmentation, cell cycle arrest and apoptosis indicate that, Bacoside A may induce cell death in GBM. Both the levels of Notch genes and morphological changes in GBM cells after treatment with Bacoside A suggest a Notch-dependent cytotoxicity. This is also proved by the flow cytometric analysis showing cell cycle arrest and early apoptosis. Thus, Bacoside A via a novel mechanism of regulating Notch gene expression may provide a promising lead for GBM therapy. These findings thus provide new insights into the possible molecular mechanism of the cytotoxic activity of Bacoside A on GBM cells.

However, there are few limitations that need to be reported which could help in shaping the future research agenda. The effects of Bacoside A on the basic components of cell cycle regulation including cyclin-dependent kinases and their regulators, and apoptosis including caspases should be studied. To obtain the first mechanistic insights into the scenarios of Bacoside A induced cell death *in vitro*, a cell line that is well-established and most widely used in GBM studies was chosen. With these preliminary data, the efficacy of the compound should be subsequently extended to observe the effects on other GBM cell lines particularly IDH mutant and wild-type.
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![Apoptosis in untreated (A) and treated U-87 MG cells with 80 µg/mL (B) and 100 µg/mL (C) of Bacoside A respectively for 24 h as determined by flow cytometry.](btrt-7-25-g004){#F4}

![U-87 MG cells treated with Bacoside A stained with Annexin V-FITC/PI displaying early apoptotic cells (A), late apoptotic/necrotic cells (B) and dead cells (C) as observed under a fluorescent microscope. Scale bar, 50 µm.](btrt-7-25-g005){#F5}
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###### Cytotoxicity of bacoside A on human glioblastoma multiforme cell line U-87 MG as determined by MTT assay

![](btrt-7-25-i001)

  No   Concentration (μg/mL)   Absorbance at 490 nm   \% Cell inhibition   \% Cell viability   IC~50~ (μg/mL)
  ---- ----------------------- ---------------------- -------------------- ------------------- ----------------
  1    320                     0.1753                 74.21                25.79               83.01
  2    160                     0.2957                 56.50                43.50               
  3    80                      0.3703                 45.53                54.47               
  4    40                      0.4758                 30.01                69.99               
  5    20                      0.5498                 19.12                80.88               
  6    10                      0.6157                 9.43                 90.57               
  7    5                       0.6515                 4.16                 95.84               
  8    Control                 0.6798                 0.00                 100.00              

Values are the mean of triplicates.

###### Expression of Notch genes in U-87 MG cells after treatment with 80 µg/mL of Bacoside A at 24 h incubation in terms of fold change

![](btrt-7-25-i002)

  Genes      Status   Fold change
  ---------- -------- -------------
  *Notch1*   ↓        0.05
  *Notch2*   ↔        1.61
  *Notch3*   ↑        3.53
  *Notch4*   ↑        2.60
  *JAG1*     ↑        2.08
  *JAG2*     ↔        1.60
  *HES1*     ↑        25.81
  *APH1A*    ↔        1.67

Values were derived from qPCR. ↑, upregulated with respect to untreated sample (\>2); ↓, downregulated with respect to untreated sample (\<0.5); ↔, no significant change with respect to untreated sample (0.5--2)
